-
公开(公告)号：US06946118B1
公开(公告)日：2005-09-20
申请号：US09661836
申请日：2000-09-14
IPC分类号： A61K9/00 , A61K9/16 , A61K31/65 , A61K47/36 , A61P1/00 , A61K9/14 , A61K7/16 , A61K9/10 , A61K9/20
CPC分类号： A61K31/65 , A61K9/006 , A61K9/0095 , A61K9/1652 , A61K9/1676 , A61K47/36 , Y10S514/901
摘要： Mucositis is treated and/or prevented by administrating to a patient a formulation comprising a tetracycline that is poorly absorbed from the gastro-intestinal tract. The tetracycline may be in the form of a pharmaceutically acceptable salt or a base. The formulations may optionally also contain an antifungal agent to prevent fungal overgrowth due to reduction in the normal oral flora by the tetracycline. Such compositions have the advantage of treating the entire gastro-intestinal tract since the active ingredient is not removed from the tract via absorption. Further, such compositions minimize systemic exposure and accompanying side effects.
摘要翻译： 通过向患者施用包含从胃肠道吸收不良的四环素的制剂来治疗和/或预防粘膜炎。 四环素可以是药学上可接受的盐或碱的形式。 制剂还可任选地含有抗真菌剂，以防止由四环素引起的正常口腔菌群减少引起的真菌过度生长。 这样的组合物具有治疗整个胃肠道的优点，因为活性成分不通过吸收从道路中除去。 此外，这样的组合物使全身暴露和伴随的副作用最小化。
-
公开(公告)号：US20090098203A1
公开(公告)日：2009-04-16
申请号：US12122232
申请日：2008-05-16
申请人： James Ronald Lawter
发明人： James Ronald Lawter
CPC分类号： A61K9/1652 , A61K9/0007 , A61K9/006 , A61K9/19 , A61K9/2018 , A61K9/205 , A61K9/2063 , A61K31/65 , A61K47/36
摘要： Mucositis is treated and/or prevented by administrating to a patient a formulation containing a tetracycline and at least one cationic polymer and/or mucoadhesive material. The tetracycline may be in the form of a pharmaceutically acceptable salt or a base. The formulations may optionally also contain an antifungal agent to prevent fungal overgrowth due to reduction in the normal oral flora by the tetracycline. The formulation can be formed into liquid or solid dosage forms such as mouth rinse or tablet. Such compositions have the advantage of prolonged retention of the tetracycline in the mucosa of the oral cavity.
摘要翻译： 通过向患者施用含有四环素和至少一种阳离子聚合物和/或粘膜粘附材料的制剂来治疗和/或预防粘膜炎。 四环素可以是药学上可接受的盐或碱的形式。 制剂还可任选地含有抗真菌剂，以防止由四环素引起的正常口腔菌群减少引起的真菌过度生长。 制剂可形成液体或固体剂型，如口腔冲洗液或片剂。 这些组合物具有将四环素延长至口腔粘膜中的优点。
-
公开(公告)号：US5942253A
公开(公告)日：1999-08-24
申请号：US542445
申请日：1995-10-12
IPC分类号： A61K9/14 , A61K9/16 , A61K31/00 , A61K38/19 , A61K38/22 , A61K47/34 , A61P37/00 , A61P37/04 , A61K9/50 , A61F2/02 , A61K9/48
CPC分类号： A61K9/0019 , A61K38/193 , A61K9/0024 , A61K9/06 , A61K9/1635 , A61K9/1641 , A61K9/1647 , Y10T428/2989
摘要： Formulations for controlled, prolonged release of GM-CSF have been developed. These are based on solid microparticles formed of the combination of biodegradable, synthetic polymers such as poly(lactic acid) (PLA), poly(glycolic acid) (PGA), and copolymers thereof with excipients and drug loadings that yield zero order or first order release, or multiphasic release over a period of approximately three to twenty one days, preferably one week, when administered by injection. In the preferred embodiment, the microparticles are microspheres having diameters in the range of 10 to 60 microns, formed of a blend of PLGA having different molecular weights, most preferably 6,000, 30,000 and 41,000. Other embodiments have been developed to alter the release kinetics or the manner in which the drug is distributed in vivo. For example, in some cases a polymer is selected which elicits a mild inflammatory reaction, for example, PLGA and polyanhydrides can act as chemoattractant, either due to the polymer itself or minor contaminants in the polymer, or polymers which are bioadhesive are used for transmucosal or oral delivery. In another embodiment, the GM-CSF is administered in a hydrogel which can be injected subcutaneous or at a specific site for controlled release. The microparticles or hydrogel are administered to the patient in an amount effect to stimulate proliferation of hematopoietic cells, especially white cells.
摘要翻译： 已经开发了控制，长期释放GM-CSF的制剂。 这些基于由生物可降解的合成聚合物如聚（乳酸）（PLA），聚（乙醇酸）（PGA））及其与赋形剂的共聚物和药物负载的组合形成的固体微粒，其产生零级或一级 当通过注射给药时，在约3至20天，优选1周的时间内释放或多相释放。 在优选的实施方案中，微粒是具有10至60微米范围内的直径的微球，由具有不同分子量，最优选6,000,300和41,000的PLGA的共混物形成。 已经开发了其它实施方案来改变药物在体内分布的释放动力学或方式。 例如，在一些情况下，选择引起轻度炎症反应的聚合物，例如PLGA和聚酐可以作为化学引诱剂，这是由于聚合物本身或聚合物中的微量污染物，或生物粘附剂的聚合物用于经粘膜 或口服。 在另一个实施方案中，GM-CSF以可以皮下注射或在特定部位注射用于控制释放的水凝胶施用。 将微粒或水凝胶以刺激造血细胞，特别是白细胞增殖的量施用于患者。
-
公开(公告)号：US06893665B2
公开(公告)日：2005-05-17
申请号：US10007197
申请日：2001-12-04
CPC分类号： A61K31/65 , A61K9/006 , A61K9/0095 , A61K9/1652 , A61K9/1676 , A61K47/36 , Y10S514/901
摘要： Mucositis is treated and/or prevented by administrating to a patient a formulation comprising a tetracycline that is poorly absorbed from the gastro-intestinal tract. The tetracycline may be in the form of a pharmaceutically acceptable salt or a base. The formulations may optionally also contain an antifungal agent to prevent fungal overgrowth due to reduction in the normal oral flora by the tetracycline. Such compositions have the advantage of treating the entire gastro-intestinal tract since the active ingredient is not removed from the tract via absorption. Further, such compositions minimize systemic exposure and accompanying side effects.
-
公开(公告)号：US06683067B2
公开(公告)日：2004-01-27
申请号：US09815762
申请日：2001-03-23
IPC分类号： A61K3105
CPC分类号： A61K31/65 , A61K9/006 , A61K9/0095 , A61K9/1652 , A61K9/1676 , A61K47/36 , Y10S514/901
摘要： Mucositis is treated and/or prevented by administrating to a patient a formulation comprising a tetracycline that is poorly absorbed from the gastro-intestinal tract. The tetracycline may be in the form of a pharmaceutically acceptable salt or a base. The formulations may optionally also contain an antifungal agent to prevent fungal overgrowth due to reduction in the normal oral flora by the tetracycline. Such compositions have the advantage of treating the entire gastro-intestinal tract since the active ingredient is not removed from the tract via absorption. Further, such compositions minimize systemic exposure and accompanying side effects.
摘要翻译： 通过向患者施用包含从胃肠道吸收不良的四环素的制剂来治疗和/或预防粘膜炎。 四环素可以是药学上可接受的盐或碱的形式。 制剂还可任选地含有抗真菌剂，以防止由四环素引起的正常口腔菌群减少引起的真菌过度生长。 这样的组合物具有治疗整个胃肠道的优点，因为活性成分不通过吸收从道路中除去。 此外，这样的组合物使全身暴露和伴随的副作用最小化。
-
-
-
-
搜索结果
5 条记录 (耗时 0.012 秒)
